IP Library Granted Patent US 11,808,760
Granted Patent B1
US 11,808,760 · App. 16/791,896 · Granted Nov 7, 2023

System and methods for in vitro structural toxicity testing

Inventors: Seyyedeh Mahnaz Maddah (Los Altos, CA); Kevin Edward Loewke (Redwood City, CA)
Assignee: CURI BIO, INC.
G01N33/5014G01N33/5026G06F18/217G06F18/2431G06N3/08G06N20/00G06T7/0016G06T2207/20081G06T2207/20084G06T2207/30024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,808,760
App. No.
16/791,896
Granted
Nov 7, 2023
Kind
B1
Abstract

A system and process use artificial intelligence to evaluate the toxicity of drugs on cells. In some embodiments, a convolutional neural network is trained to identify features in cells and thereafter identify when structural changes in cells are signs of damage from exposure to a drug. Some embodiments use a 2-class deep neural network, comparing drug-treated cells to controls, to learn which images may show signs of toxicity as a result of the drug. In some applications, the system may capture images from a time-lapse experiment to determine from the cell cultures how a drug affects a cell type over time.

Claims (31)

1 . A computer program product to determine a response of a cell to a drug, the computer program product comprising a non-transitory computer readable storage medium having computer readable program code embodied therewith, the computer readable program code being configured, when executed by a processor, to:

receive images of treated cells, wherein the treated cells are exposed to the drug, at an initial point in time;

receive images of control cells not exposed to the drug;

forward the images of the treated cells and the images of the control cells to a convolutional neural network;

determine by the convolutional neural network whether the images of the treated cells are different from the images of the control cells; and

calculate a metric based on the determination by the convolutional neural network quantifying an amount of change caused by the drug on the treated cells.

2 . The computer program product of claim 1 , further comprising computer readable program code configured to:

wherein the treated cells are exposed to multiple dosages of the drug and the determination is by a series of convolutional neural networks and includes quantifying changes associated with each of the multiple dosages.

3 . The computer program product of claim 1 , wherein the treated cells are exposed to multiple types of drugs and the determination is by a series of convolutional neural networks and includes quantifying changes associated with each of the multiple types of drugs.

4 . The computer program product of claim 1 , wherein the determination is by a series of convolutional neural networks and includes quantifying changes at multiple points in time after the initial point in time.

5 . The computer program product of claim 1 , wherein:

the received images of the treated cells and the received images of the control cells are received on multiple image channel types; and

the determination is by a series of convolutional neural networks and includes quantifying changes shown in each channel type.

6 . The computer program product of claim 1 , wherein the metric calculated is a z-factor measure.

7 . The computer program product of claim 1 , wherein the convolutional neural network uses a 2-class classification basis.

8 . The computer program product of claim 1 , wherein the metric calculated is Tjur’s pseudo R2.

9 . A method for determining an automated response of a cell to a drug, comprising:

receiving images of treated cells, wherein treated cells are exposed to the drug, at an initial point in time;

receiving images of control cells not exposed to the drug;

forwarding the images of the treated cells and the images of the control cells to a convolutional neural network;

determining by the convolutional neural network whether the images of the treated cells are different from the images of the control cells; and

calculating a metric based on the determination by the convolutional neural network quantifying an amount of change caused by the drug on the treated cells.

10 . The method of claim 9 , wherein the treated cells are exposed to multiple dosages of the drug and the determination is by a series of convolutional neural networks includes and quantifying changes associated with each of the multiple dosages.

11 . The method of claim 9 , wherein the treated cells are exposed to multiple types of drugs and the determination is by a series of convolutional neural networks and includes quantifying changes associated with each of the multiple types of drugs.

12 . The method of claim 9 , wherein the determination is by a series of convolutional neural networks and includes quantifying changes at multiple points in time after the initial point in time.

13 . The method of claim 9 , wherein:

the received images of the treated cells and the received images of the control cells are received on multiple image channel types; and

the determination is by a series of convolutional neural networks and includes quantifying changes shown in each channel type.

14 . The method of claim 9 , wherein the metric calculated is a z-factor measure.

15 . The method of claim 9 , wherein the convolutional neural network uses a 2-class classification basis.

16 . The method of claim 9 , wherein the metric calculated is Tjur’s pseudo R2.

Assignments (3)
MERGER Recorded Jul 11, 2022
From: DANA SOLUTIONS LLC
To: NANOSURFACE BIOMEDICAL, INC.
Reel/Frame 060468/0381 →
CHANGE OF NAME Recorded Jul 11, 2022
From: NANOSURFACE BIOMEDICAL, INC.
To: CURI BIO, INC.
Reel/Frame 060621/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: MADDAH, SEYYEDEH MAHNAZ; LOEWKE, KEVIN EDWARD
To: DANA SOLUTIONS, LLC.
Reel/Frame 051826/0651 →
Continuity (1)
Provisional Application 62805427 · Feb 14, 2019